pyrroles has been researched along with Esophageal Reflux in 41 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 24 (58.54) | 24.3611 |
| 2020's | 17 (41.46) | 2.80 |
| Authors | Studies |
|---|---|
| Facius, A; Howden, CW; Lahu, G; Leifke, E; Mulford, DJ; Scarpignato, C; Smith, N | 1 |
| Demura, M; Esaka, N; Fujii, H; Hamada, H; Harada, N; Hirai, Y; Inoue, S; Kagaya, T; Kato, M; Kubo, K; Kuwai, T; Mabe, K; Matsuda, S; Matsumoto, M; Mori, H; Sakakibara, Y; Sasaki, Y; Toyokawa, T; Watanabe, N; Yamashita, H | 1 |
| Deguchi, H; Fernandez, J; Fujimori, I; Igarashi, A; Nakano, H; Oshima, T | 1 |
| Cash, BD; Merchant, A; Ramani, A | 1 |
| Armstrong, D; Fass, R; Harris, T; Hunt, B; Leifke, E; Sharma, P; Smith, N; Vaezi, M; Yadlapati, R | 1 |
| Armstrong, D; Fass, R | 1 |
| Kahrilas, PJ | 1 |
| Bai, T; Hou, X; Liu, X; Wang, D; Xu, Z; Zhou, D | 1 |
| Deguchi, H; Higuchi, K; Igarashi, A; Takeuchi, T; Uda, A; Yokoya, Y | 1 |
| Tytgat, GNJ | 1 |
| Chinen, T; Hamada, S; Ihara, E; Ikeda, H; Muta, K; Ogawa, Y; Ogino, H; Tanaka, Y | 1 |
| Kato, M; Kimura, N; Kubo, K; Mabe, K; Matsuda, S; Tsuda, M | 1 |
| Araki, T; Ashida, K; Iwakiri, K; Kinoshita, Y; Kudou, K; Miyagi, T; Sakurai, Y; Takabayashi, N | 1 |
| Abe, Y; Asano, N; Asanuma, K; Hatta, W; Imatani, A; Koike, T; Masamune, A; Nakagawa, K; Okata, T; Saito, M; Uno, K | 1 |
| Cheng, Y; Dai, Y; Jiang, H; Kou, F; Li, J; Li, X; Liu, J; Lu, Q; Tan, X; Xie, C | 1 |
| Gotoh, Y; Honda, S; Ishibashi, E; Kagawa, K; Murakami, K; Nakaya, T; Noguchi, C | 1 |
| Miwa, H; Oshima, T | 1 |
| Hongo, M; Hunt, RH; Lazarescu, A; Lottrup, C; Scarpignato, C; Stein, E; Wu, JCY | 1 |
| Hoshikawa, Y; Hoshino, S; Iwakiri, K; Kawami, N | 1 |
| Fujiwara, Y; Hasegawa, T; Inoue, A; Ishizu, H; Iwakura, N; Nakahara, K; Okuyama, M; Oyama, M; Satoh, H | 1 |
| Blandizzi, C; Bodini, G; de Bortoli, N; Marabotto, E; Marchi, S; Martinucci, I; Savarino, E; Savarino, V | 1 |
| D'Angelo, F; Frossard, JL; Gkouvatsos, K; Guglielmi, S | 1 |
| Furuta, T; Hamaya, Y; Iwaizumi, M; Kagami, T; Miyajima, H; Osawa, S; Sugimoto, K; Suzuki, T; Uotani, T; Yamade, M | 1 |
| Hayashi, Y; Lefor, AK; Miura, Y; Osawa, H; Sakamoto, H; Shinozaki, S; Yamamoto, H | 1 |
| Kato, M; Kudo, T; Matsuno, Y; Miyamoto, S; Ono, S; Sakamoto, N; Shimizu, Y | 1 |
| Fujishiro, M; Hayakawa, Y; Hirata, Y; Koike, K; Niikura, R; Shinozaki, T; Takahashi, A; Takeuchi, Y; Yamada, A | 1 |
| Ashida, K; Hiramatsu, N; Hori, T; Iwakiri, K; Kudou, K; Nishimura, A; Sakurai, Y; Umegaki, E | 1 |
| Ishihara, S; Ishimura, N; Kinoshita, Y | 1 |
| Hayashi, Y; Kawarai Lefor, A; Kobayashi, Y; Miura, Y; Osawa, H; Sakamoto, H; Shinozaki, S; Yamamoto, H | 1 |
| Choi, G; Kang, H; Kim, BJ; Kim, JG | 1 |
| Fujie, S; Hasuda, K; Hattori, M; Hirano, M; Ito, K; Murao, T; Okuda, A; Sakurai, K; Suda, H; Takeichi, T; Tsuruta, K | 1 |
| Arai, E; Fukui, H; Kondo, T; Miwa, H; Oshima, T; Taki, M; Tomita, T; Watari, J | 1 |
| Hoshikawa, Y; Hoshino, S; Iwakiri, K; Kaise, M; Kawami, N; Tanabe, T; Umezawa, M | 1 |
| Deguchi, H; Higuchi, K; Igarashi, A; Miyazaki, H; Takeuchi, T; Tango, T; Teng, L; Uda, A | 1 |
| Akiyama, J; Hisada, Y; Hosaka, H; Imbe, K; Kawamura, O; Kojima, Y; Kuribayashi, S; Kusano, M; Moriyasu, S; Nagata, N; Okubo, H; Shimoyama, Y; Uemura, N; Watanabe, K; Yamada, M; Yokoi, C | 1 |
| Deguchi, H; Igarashi, A; Miwa, H; Tango, T; Teng, L; Uda, A | 1 |
| Habu, Y | 1 |
| Sugano, K | 1 |
| Kondo, T; Miwa, H; Oshima, T | 1 |
| Bernatsky, S; Curtis, JR; Xie, F; Yun, H | 1 |
| Inatomi, N; Munson, K; Sachs, G; Shin, JM; Strugatsky, D; Tokhtaeva, E; Vagin, O | 1 |
10 review(s) available for pyrroles and Esophageal Reflux
| Article | Year |
|---|---|
Network Meta-analysis Comparing Vonoprazan and Proton Pump Inhibitors for Heartburn Symptoms in Erosive Esophagitis.
Topics: Adult; Bayes Theorem; Esophagitis; Gastroesophageal Reflux; Heartburn; Humans; Network Meta-Analysis; Proton Pump Inhibitors; Pyrroles; Rabeprazole; Randomized Controlled Trials as Topic; Sulfonamides; Treatment Outcome | 2022 |
Review of the clinical development of fexuprazan for gastroesophageal reflux-related disease.
Topics: Esophagitis; Gastroesophageal Reflux; Humans; Peptic Ulcer; Proton Pump Inhibitors; Pyrroles | 2023 |
Direct Comparison of the Efficacy and Safety of Vonoprazan Versus Proton-Pump Inhibitors for Gastroesophageal Reflux Disease: A Systematic Review and Meta-Analysis.
Topics: Gastroesophageal Reflux; Heartburn; Humans; Proton Pump Inhibitors; Pyrroles; Randomized Controlled Trials as Topic; Sulfonamides; Treatment Outcome | 2021 |
Pharmacologic treatment of GERD: Where we are now, and where are we going?
Topics: Cimetidine; Esomeprazole; Esophageal Mucosa; Gastroesophageal Reflux; Humans; Lansoprazole; Omeprazole; Proton Pump Inhibitors; Pyrroles; Sulfonamides | 2020 |
Vonoprazan fumarate for the management of acid-related diseases.
Topics: Gastroesophageal Reflux; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors; Pyrroles; Sulfonamides; Treatment Outcome | 2017 |
[Gastroenterology and hepatology in 2016].
Topics: Biosimilar Pharmaceuticals; Disease Eradication; Drug Resistance, Bacterial; Duodenal Ulcer; Gastroenterology; Gastroesophageal Reflux; Helicobacter Infections; Helicobacter pylori; Humans; Pyrroles; Sulfonamides | 2017 |
Vonoprazan versus proton pump inhibitors for the management of gastroesophageal reflux disease: A protocol for a systematic review with meta-analysis.
Topics: Cytochrome P-450 CYP2C19; Esophagus; Gastroesophageal Reflux; Humans; Proton Pump Inhibitors; Pyrroles; Randomized Controlled Trials as Topic; Sulfonamides; Systematic Reviews as Topic | 2018 |
Vonoprazan versus proton-pump inhibitors for healing gastroesophageal reflux disease: A systematic review.
Topics: Bayes Theorem; Esophagitis, Peptic; Gastroesophageal Reflux; Humans; Network Meta-Analysis; Patient Selection; Proton Pump Inhibitors; Pyrroles; Randomized Controlled Trials as Topic; Remission Induction; Severity of Illness Index; Sulfonamides; Time Factors; Treatment Outcome; Wound Healing | 2019 |
Systematic review with network meta-analysis: indirect comparison of the efficacy of vonoprazan and proton-pump inhibitors for maintenance treatment of gastroesophageal reflux disease.
Topics: Gastroesophageal Reflux; Humans; Proton Pump Inhibitors; Pyrroles; Randomized Controlled Trials as Topic; Sulfonamides | 2019 |
Gastroesophageal reflux disease-related and functional heartburn: pathophysiology and treatment.
Topics: Esophageal pH Monitoring; Esophagus; Gastric Acidity Determination; Gastroesophageal Reflux; Heartburn; Humans; Mucous Membrane; Proton Pump Inhibitors; Pyrroles; Sulfonamides; Treatment Outcome | 2016 |
10 trial(s) available for pyrroles and Esophageal Reflux
| Article | Year |
|---|---|
A study for every second day administration of vonoprazan for maintenance treatment of erosive GERD (ESD von GERD): a multicenter randomized cross-over study.
Topics: Cross-Over Studies; Gastroesophageal Reflux; Humans; Prospective Studies; Proton Pump Inhibitors; Pyrroles; Sulfonamides; Treatment Outcome | 2022 |
Randomised clinical trial: Efficacy and safety of on-demand vonoprazan versus placebo for non-erosive reflux disease.
Topics: Gastroesophageal Reflux; Heartburn; Humans; Proton Pump Inhibitors; Pyrroles; Sulfonamides; Treatment Outcome | 2023 |
Different dosages of vonoprazan for gastroesophageal reflux disease: study protocol for a pragmatic, crossover-cluster, randomized controlled trial with patient preference arms.
Topics: Gastroesophageal Reflux; Humans; Patient Preference; Proton Pump Inhibitors; Pyrroles; Randomized Controlled Trials as Topic; Treatment Outcome | 2023 |
Efficacy and Safety of Vonoprazan in Patients With Nonerosive Gastroesophageal Reflux Disease: A Randomized, Placebo-Controlled, Phase 3 Study.
Topics: Dose-Response Relationship, Drug; Double-Blind Method; Endoscopy, Gastrointestinal; Female; Gastroesophageal Reflux; Heartburn; Humans; Male; Middle Aged; Pyrroles; Sulfonamides; Treatment Outcome | 2019 |
Factors Associated with Potassium-Competitive Acid Blocker Non-Response in Patients with Proton Pump Inhibitor-Refractory Gastroesophageal Reflux Disease.
Topics: Aged; Aged, 80 and over; Female; Gastroesophageal Reflux; Humans; Male; Middle Aged; Proton Pump Inhibitors; Pyrroles; Sleep Wake Disorders; Sulfonamides; Treatment Failure | 2017 |
Comparison of effect of an increased dosage of vonoprazan versus vonoprazan plus lafutidine on gastric acid inhibition and serum gastrin.
Topics: Acetamides; Adolescent; Adult; Cross-Over Studies; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Gastric Acid; Gastric Acidity Determination; Gastrins; Gastroesophageal Reflux; Healthy Volunteers; Histamine H2 Antagonists; Humans; Hydrogen-Ion Concentration; Male; Piperidines; Proton Pump Inhibitors; Pyridines; Pyrroles; Sulfonamides; Young Adult | 2018 |
Vonoprazan treatment improves gastrointestinal symptoms in patients with gastroesophageal reflux disease.
Topics: Endoscopy; Female; Gastroesophageal Reflux; Humans; Male; Middle Aged; Pyrroles; Sulfonamides | 2017 |
Maintenance for healed erosive esophagitis: Phase III comparison of vonoprazan with lansoprazole.
Topics: Adult; Aged; Biopsy; Double-Blind Method; Esophagitis, Peptic; Esophagoscopy; Esophagus; Female; Gastric Mucosa; Gastroesophageal Reflux; Heartburn; Humans; Incidence; Lansoprazole; Male; Middle Aged; Proton Pump Inhibitors; Pyrroles; Recurrence; Sulfonamides; Treatment Outcome | 2018 |
Short-Term Symptomatic Relief in Gastroesophageal Reflux Disease: A Comparative Study of Esomeprazole and Vonoprazan.
Topics: Adult; Aged; Esomeprazole; Female; Gastroesophageal Reflux; Humans; Japan; Male; Middle Aged; Prospective Studies; Proton Pump Inhibitors; Pyrroles; Remission Induction; Self Report; Sulfonamides; Time Factors; Treatment Outcome | 2019 |
Randomised clinical trial: vonoprazan versus lansoprazole for the initial relief of heartburn in patients with erosive oesophagitis.
Topics: Adult; Aged; Double-Blind Method; Esophagitis; Female; Gastroesophageal Reflux; Heartburn; Humans; Lansoprazole; Male; Middle Aged; Proton Pump Inhibitors; Pyrroles; Sulfonamides | 2019 |
21 other study(ies) available for pyrroles and Esophageal Reflux
| Article | Year |
|---|---|
A Population Pharmacokinetic Model of Vonoprazan: Evaluating the Effects of Race, Disease Status, and Other Covariates on Exposure.
Topics: Esophagitis; Gastroesophageal Reflux; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors; Pyrroles; Sulfonamides | 2022 |
Editorial: On-demand vonoprazan for NERD - when should it be 'demanded'? Authors' reply.
Topics: Gastroesophageal Reflux; Humans; Proton Pump Inhibitors; Pyrroles; Sulfonamides | 2023 |
Editorial: On-demand vonoprazan for NERD-when should it be 'demanded'?
Topics: Gastroesophageal Reflux; Humans; Proton Pump Inhibitors; Pyrroles; Sulfonamides | 2023 |
Cost-utility analysis of a 'vonoprazan-first' strategy versus 'esomeprazole- or rabeprazole-first' strategy in GERD.
Topics: Computer Simulation; Cost-Benefit Analysis; Esomeprazole; Gastroesophageal Reflux; Humans; Japan; Markov Chains; Proton Pump Inhibitors; Pyrroles; Quality-Adjusted Life Years; Rabeprazole; Recurrence; Sulfonamides; Time Factors; Treatment Outcome | 2019 |
Highlights from Gastro Update Europe - Budapest June 26-27, 2019.
Topics: Celiac Disease; Clostridioides difficile; Colorectal Neoplasms; Endoscopy, Digestive System; Enterocolitis, Pseudomembranous; Foodborne Diseases; Gastroesophageal Reflux; Gastrointestinal Diseases; Humans; Pancreatic Intraductal Neoplasms; Pancreatitis; Proton Pump Inhibitors; Pyrimidinones; Pyrroles; Sulfonamides; Tetrahydroisoquinolines | 2019 |
Clinical Characterization of Vonoprazan-Refractory Gastroesophageal Reflux Disease.
Topics: Esophageal pH Monitoring; Gastroesophageal Reflux; Humans; Proton Pump Inhibitors; Pyrroles; Retrospective Studies; Sulfonamides; Treatment Outcome | 2021 |
Vonoprazan-associated Gastric Mucosal Redness: A Report of Four Cases.
Topics: Aged; Aged, 80 and over; Endoscopy, Digestive System; Female; Gastric Mucosa; Gastroesophageal Reflux; Humans; Inflammation; Male; Proton Pump Inhibitors; Pyrroles; Sulfonamides; Treatment Outcome | 2020 |
The Ameliorating Effect of Switching to Vonoprazan: A Novel Potassium-Competitive Acid Blocker in Patients with Proton Pump Inhibitor Refractory Non-Erosive Reflux Disease.
Topics: Esophageal pH Monitoring; Gastroesophageal Reflux; Humans; Potassium; Proton Pump Inhibitors; Pyrroles; Retrospective Studies; Sulfonamides | 2021 |
Efficacy of vonoprazan for initial and maintenance therapy in reflux esophagitis, nonerosive esophagitis, and proton pump inhibitor-resistant gastroesophageal reflux disease.
Topics: Aged; Female; Gastroesophageal Reflux; Humans; Male; Proton Pump Inhibitors; Pyrroles; Severity of Illness Index; Sulfonamides; Surveys and Questionnaires; Treatment Outcome | 2020 |
How Does Vonoprazan Affect the Treatment of Erosive Esophagitis?
Topics: Esophagitis; Gastroesophageal Reflux; Humans; Proton Pump Inhibitors; Pyrroles; Sulfonamides | 2021 |
Prevalence of behavioral disorders in patients with vonoprazan-refractory reflux symptoms.
Topics: Aged; Female; Gastroesophageal Reflux; Humans; Japan; Logistic Models; Male; Mental Disorders; Middle Aged; Prevalence; Proton Pump Inhibitors; Pyrroles; Retrospective Studies; Sulfonamides | 2021 |
Parietal Cell Protrusions and Dilated Oxyntic Glands from Use of Vonoprazan.
Topics: Adult; Biopsy; Endoscopy, Gastrointestinal; Gastric Mucosa; Gastroesophageal Reflux; Humans; Male; Parietal Cells, Gastric; Proton Pump Inhibitors; Pyrroles; Sulfonamides | 2017 |
Efficacy of Vonoprazan for Gastroesophageal Reflux Symptoms in Patients with Proton Pump Inhibitor-resistant Non-erosive Reflux Disease.
Topics: Adult; Aged; Female; Gastroesophageal Reflux; Humans; Male; Middle Aged; Odds Ratio; Proton Pump Inhibitors; Pyrroles; Retrospective Studies; Self Report; Sulfonamides; Treatment Outcome | 2018 |
Management of GERD: Are Potassium-Competitive Acid Blockers Superior to Proton Pump Inhibitors?
Topics: Clinical Trials as Topic; Esophagitis, Peptic; Gastric Acid; Gastroesophageal Reflux; H(+)-K(+)-Exchanging ATPase; Half-Life; Humans; Inhibitory Concentration 50; Japan; Potassium; Prevalence; Proton Pump Inhibitors; Pyrroles; Sulfonamides; Treatment Outcome | 2018 |
Long-term outcomes of patients with symptomatic gastroesophageal reflux disease treated with vonoprazan.
Topics: Aged; Endoscopy, Gastrointestinal; Esophagitis, Peptic; Female; Gastroesophageal Reflux; Humans; Japan; Logistic Models; Male; Middle Aged; Multivariate Analysis; Proton Pump Inhibitors; Pyrroles; Quality of Life; Recurrence; Retrospective Studies; Severity of Illness Index; Sulfonamides; Surveys and Questionnaires; Wound Healing | 2018 |
Efficacy of on-demand therapy using 20-mg vonoprazan for non-erosive reflux disease.
Topics: Aged; Drug Administration Schedule; Female; Gastrins; Gastroesophageal Reflux; Humans; Male; Middle Aged; Patient Satisfaction; Prospective Studies; Proton Pump Inhibitors; Pyrroles; Sulfonamides; Treatment Outcome | 2019 |
Efficacy of Vonoprazan, a Novel Potassium-Competitive Acid Blocker, in Patients with Proton Pump Inhibitor-Refractory Acid Reflux.
Topics: Aged; Aged, 80 and over; Drug Substitution; Esophageal pH Monitoring; Esophagitis, Peptic; Female; Gastroesophageal Reflux; Humans; Male; Middle Aged; Proton Pump Inhibitors; Pyrroles; Retrospective Studies; Sulfonamides; Treatment Outcome | 2020 |
Vonoprazan versus Lansoprazole for the Initial Treatment of Reflux Esophagitis: A Cost-effectiveness Analysis in Japan.
Topics: Adult; Cost-Benefit Analysis; Drug Administration Schedule; Female; Gastroesophageal Reflux; Gastrointestinal Agents; Humans; Japan; Lansoprazole; Markov Chains; Pyrroles; Quality of Life; Sulfonamides | 2019 |
[Vonoprazan: a novel potassium-competitive acid blocker].
Topics: Clinical Trials as Topic; Gastric Acid; Gastroesophageal Reflux; Humans; Potassium Channel Blockers; Proton Pump Inhibitors; Pyrroles; Sulfonamides | 2015 |
Brief Report: Risk of Gastrointestinal Perforation Among Rheumatoid Arthritis Patients Receiving Tofacitinib, Tocilizumab, or Other Biologic Treatments.
Topics: Abatacept; Adult; Age Factors; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Biological Products; Databases, Factual; Diverticulitis; Esophageal Perforation; Female; Gastroesophageal Reflux; Glucocorticoids; Humans; Incidence; Intestinal Perforation; Male; Medicare; Middle Aged; Peptic Ulcer; Piperidines; Prednisone; Proportional Hazards Models; Pyrimidines; Pyrroles; Risk Factors; Rituximab; Tumor Necrosis Factor-alpha; United States | 2016 |
Characterization of a novel potassium-competitive acid blocker of the gastric H,K-ATPase, 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438).
Topics: Acridine Orange; Animals; Fluorescent Dyes; Gastroesophageal Reflux; H(+)-K(+)-Exchanging ATPase; HEK293 Cells; Humans; Models, Molecular; Molecular Targeted Therapy; Phosphorylation; Protein Binding; Proton Pump Inhibitors; Pyrroles; Software; Stereoisomerism; Stomach; Sulfonamides; Swine | 2011 |